Morgann joined our staff in July of 2016 to study medulloblastoma – the most common brain tumor in children – with the goal to discover new targets and safer, more effective and less toxic therapies for children. In the 18 months since joining the team, Morgann has established herself as a crucial member of the team with a never-ending drive to advance our mission.
Before joining the cc-TDI family, Morgann finished her BS and MS in Biomedical Engineering from Northwestern University. During her stay at Northwestern, she worked as a student researcher under Dr. Patrick Kiser, where she was able to hone her craft developing new drug delivery systems pertaining to women’s health. While working in Dr. Kiser’s lab, Morgann was able to focus on drug delivery, formulation science, and manufacturing and design engineering, which helped her bring a wealth of expertise to our lab.
Presently, Morgann is focused on validating recently discovered targets in medulloblastoma. She has successfully developed a technique for surgical implantation of medulloblastoma cells into the brains of mice (with the help of our new micromanipulator instrument!), and is eagerly preparing for her next mouse studies. In the meantime, she has been working on a novel in-vitro flow assay that simulates the flow of medulloblastoma and adhesion to the leptomeninges. When she’s not in the lab, Morgann enjoys skiing in the winter, hiking in the summer, cooking, and exploring cities on her weekend getaways.
cc-TDI is doing amazing work – work that could not be done without absolute rock stars dedicated to making all cancers universally survivable. Thank you, Morgann, for your constant positive attitude and persistent dedication to our mission.
Visit us. Be inspired. Donate today!
